W. A. Volkert and T. J. Hoffman, Therapeutic radiopharmaceuticals, Chem Rev, vol.99, pp.2269-92, 1999.

J. F. Chatal and C. A. Hoefnagel, Radionuclide therapy, Lancet, vol.354, pp.931-936, 1999.
URL : https://hal.archives-ouvertes.fr/inserm-01804899

S. Srivastava and E. Dadachova, Recent advances in radionuclide therapy, Semin Nucl Med, vol.31, pp.330-371, 2001.

W. J. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall et al., Targeted therapy in nuclear medicine-current status and future prospects, Ann Oncol, vol.18, pp.1782-92, 2007.

J. Elgqvist, S. Frost, J. P. Pouget, and P. Albertsson, The potential and hurdles of targeted alpha therapy -clinical trials and beyond, Front Oncol, vol.3, p.324, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168053

C. Müller, N. P. Van-der-meulen, M. Bene?ová, and R. Schibli, Therapeutic radiometals beyond 177 Lu and 90 Y: production and application of promising ?-Particle, ?-Particle, and auger electron emitters, J Nucl Med, vol.58, 2017.

F. Lacoeuille, N. Arlicot, and A. Faivre-chauvet, Targeted alpha and beta radiotherapy: an overview of radiopharmaceutical and clinical aspects, Med Nucl, vol.42, pp.32-44, 2018.

M. Makvandi, E. Dupis, J. W. Engle, F. M. Nortier, M. E. Fassbender et al., Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations, Target Oncol, vol.13, pp.189-203, 2018.

Y. Arano, Recent advances in 99m Tc radiopharmaceuticals, Ann Nucl Med, vol.16, pp.79-93, 2002.

I. Zolle, , vol.345, 2007.

M. D. Bartholomä, A. S. Louie, J. F. Valliant, and J. Zubieta, Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era, Chem Rev, vol.110, pp.2903-2923, 2010.

J. C. Vites, M. M. Lynam, and . Rhenium, Coord Chem Rev, vol.172, pp.357-88, 1996.

R. Alberto, R. Schibli, R. Waibel, A. U. Schubiger, and A. P. , Basic aqueous chemistry of [M(OH 2 ) 3 (CO) 3 ] + . (M = Re, Tc) directed towards radiopharmaceutical application, Coord Chem Rev, pp.190-192, 1999.

G. Bandoli, F. Tisato, F. Refosco, and T. Gerber, Rhenium(V) Complexes: from pure hard donors to mixed soft/hard functionalized phosphine ligands, Rev Inorg Chem, vol.19, pp.187-210, 1999.

G. Liu and D. J. Hnatowich, Labeling biomolecules with radiorhenium -a review of the bifunctional chelators, Anticancer Agents Med Chem, vol.7, pp.367-77, 2007.

E. M. Hahn, A. Casini, and F. E. Kühn, Re(VII) and Tc(VII) trioxo complexes stabilized by tridentate ligands and their potential use as radiopharmaceuticals, Coord Chem Rev, vol.276, pp.97-111, 2014.

A. Guertin, C. Duchemin, F. Haddad, N. Michel, and V. Métivier, Measurements of 186 Re production cross section induced by deuterons on nat W target at ARRONAX facility, Nucl Med Biol, vol.41, pp.16-24, 2014.

M. E. Moustapha, G. J. Ehrhardt, C. J. Smith, L. P. Szajek, W. C. Eckelman et al., Preparation of cyclotron-produced 186 Re and comparison with reactorproduced 186 Re and generator-produced 188 Re for the labeling of bombesin, Nucl Med Biol, vol.33, pp.81-90, 2006.

J. R. Dilworth and S. J. Parrott, The biomedical chemistry of technetium and rhenium, Chem Soc Rev, vol.27, pp.43-55, 1998.

F. Mévellec, N. Lepareur, A. Roucoux, N. Noiret, H. Patin et al., Chelated hydrazido(3-)rhenium(V) complexes: on the way to the nitrido-M(V) core (M = Tc, Re), vol.41, pp.1591-1598, 2002.

J. H. Wang, R. Eychenne, M. Wolff, S. Mallet-ladeira, N. Lepareur et al., Design, synthesis, and reactivity of multidentate ligands with Rhenium(I) and Rhenium(V) Cores, Eur J Inorg Chem, pp.3908-3926, 2017.

E. Deutsch, K. Libson, J. L. Vanderheyden, A. R. Ketring, and H. R. Maxon, The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine, Nucl Med Biol, vol.13, issue.86, pp.90027-90036, 1986.

D. Rosales, R. Blower, and P. , Role of 99m Tc in the development of rhenium radiopharmaceuticals, Technetium-99m Radiopharmaeuticals: Status and Trends. Vienna: IAEA Radioisotopes and Radiopharmaceuticals Series, p.1, 2010.

. Helm-l.-;-+-.-(m-=-mn, Ligand exchange and complex formation kinetics studied by NMR exemplified on fac, Coord Chem Rev, vol.252, pp.2346-61, 2008.

P. S. Donnelly, The role of coordination chemistry in the development of copper and rhenium radiopharmaceuticals, Dalton Trans, vol.40, pp.999-1010, 2011.

P. J. Blower, Rhenium-188 radiochemistry: challenges and prospects, Int J Nucl Med Res, pp.39-53, 2017.

F. Knapp and ). Russ, Rhenium-188 -a generator-derived radioisotope for cancer therapy cancer, Cancer Biother Radiopharm, vol.13, pp.337-386, 1998.

M. Pillai, A. Dash, and F. F. Knapp, Rhenium-188: availability from the 188 W/ 188 Re generator and status of current applications, Curr Radiopharm, vol.5, pp.228-231, 2012.

F. Knapp, ). Russ, J. Kropp, and K. Liepe, Rhenium-188 generatorbased radiopharmaceuticals for therapy, Medical Radiology, 2012.

M. Argyrou, A. Valassi, M. Andreou, and M. Lyra, Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy, Int J Mol Imaging, vol.3, p.290750, 2013.

A. Dash, F. Knapp, and ). Russ, An overview of radioisotope separation technologies for development of 188 W/ 188 Re radionuclide generators providing 188 Re to meet future research and clinical demands, vol.5, pp.39012-39048, 2015.

F. Knapp and . Russ, Continued availability of the tungsten-188/rhenium-188 generator to enhance therapeutic utility of 188 Re Int, J Nucl Med Res, pp.3-15, 2017.

A. Shinto and A. Pillai, Rhenium-188 as a therapeutic radionuclide in lowincome and middle-income countries, Nucl Med Commun, vol.39, pp.1-2, 2018.

F. Knapp, ). Russ, S. Mirzadeh, and A. L. Beets, Reactor production and processing of therapeutic radioisotopes for applications in nuclear medicine, J Radioanal Nucl Chem, vol.205, pp.93-100, 1996.

F. Knapp, ). Russ, S. Mirzadeh, A. L. Beets, and M. Du, Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor. (HFIR) for applications in nuclear medicine, oncology and interventional cardiology, J Radioanal Nucl Chem, vol.263, pp.503-512, 2005.

F. Knapp, ). Russ, S. Mirzadeh, M. Garland, and R. Kuznetsov, Reactor Production and Processing of 188 W. In: Production of Long Lived Parent Radionuclides for Generators: 68 Ge, 82 Sr, 90 Sr and 188 W, International Atomic Energy Agency. Vienna: (IAEA) Radioisotopes and Radiopharmaceutical Series, issue.2, 2010.

S. Mirzadeh, F. Knapp, ). Russ, and R. M. Lambrecht, Burn-up Cross Section of 188 W, Radiochim Acta, vol.77, pp.99-102, 1997.

F. Knapp, ). Russ, J. H. Turner, J. M. Jeong, and A. K. Padhy, Issues associated with the use of the Tungsten-188/Rhenium188 generator and concentrator system and preparation of Re-188 HDD: A report, World J Nucl Med, vol.3, pp.137-143, 2004.

S. Mirzadeh, M. Du, A. L. Beets, and F. F. Knapp, Russ) Jr. Thermoseparation of neutron-irradiated tungsten from Re and Os, Indust Engineer Chem Res, vol.39, pp.3169-72, 2000.

B. Ponsard, J. Hiltunen, P. Penttilla, H. Vera-ruiz, A. L. Beets et al., The tungsten-188/rhenium-188 generator: effective coordination of tungsten-188 production between the HFIR and BR2 Reactors, J Radioanal Nucl Chem, vol.257, pp.169-174, 2003.

R. E. Lewis and J. S. Eldridge, Production of 70-day W-188 and development of a 17-hour Re-188 radioisotope generator, J Nucl Med, vol.7, pp.804-809, 1966.

F. Knapp, ). Russ, A. P. Callahan, A. L. Beets, S. Mirzadeh et al., Processing of reactor-produced tungsten-188 for fabrication of clinical scale alumina-based tungsten-188/Rhenium-188 generators, Appl Radiat Isot, vol.45, pp.1123-1131, 1994.

A. Mushtaq, Recovery of enriched 186 W from spent 188 W/ 188 Re generators, Appl Radiat Isot, vol.47, pp.727-736, 1996.

H. Kamioki, S. Mirzadeh, R. M. Lambrecht, F. Knapp, ). Russ et al., Tungsten-188/Rhenium-188 generator for biomedical applications, Radiochim Acta, vol.65, pp.39-46, 1994.

J. S. Lee, J. S. Lee, U. J. Park, K. J. Son, and H. S. Han, Development of a high performance 188 W/ 188 Re generator using synthetic alumina, Appl Radiat Isot, vol.67, pp.1162-1168, 2009.

B. Jäckel, R. Cripps, S. Güntay, and H. Bruchertseifer, Development of semiautomated system for preparation of 188 Re aqueous solutions of high and reproducible activity concentrations, Appl Radiat Isot, vol.63, pp.299-304, 2005.

T. Y. Luo, A. R. Lo, B. T. Hsieh, and W. J. Lin, A design for automatic preparation of highly concentrated 188 Re-perrhenate solutions, Appl Radiat Isot, vol.65, pp.21-26, 2007.

G. Wunderlich, H. Hartmann, M. Andreef, and J. Kotzerke, A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications, Appl Radiat Isot, vol.66, pp.1876-80, 2008.

J. Singh, K. Reghebi, C. R. Lazarus, S. Clarke, A. P. Callahan et al., Studies on the preparation and isomeric composition of [ 186 Re]-and [ 188 Re]-pentavalent rhenium dimercaptosuccinic acid complex, Nucl Med Commun, vol.14, pp.197-203, 1993.

F. Knapp, ). Russ, S. Guhlke, J. Weinberger, A. L. Beets et al., High specific volume rhenium-188 -clinical potential of a readily available therapeutic radioisotope Nuklearmedizin, vol.36, p.38, 1997.

P. J. Blower, Extending the life of a 99m Tc generator: a simple and convenient method for concentrating generator eluate for clinical use, Nucl Med Commun, vol.14, pp.995-1002, 1993.

S. Guhlke and . Be, Simple new method for effective concentration of 188 Re solutions from alumina-based 188 W-188 Re Generator, J Nucl Med, vol.41, pp.1271-1278, 2000.

, Nucl Med Commun, vol.25, pp.957-62, 2004.

S. K. Sarkar, M. Venkatesh, and N. Ramammorthy, Evaluation of two methods for concentrating perrhenate. ( 188 Re) eluates obtained from 188 W-188 Re generator, Appl Radiat Isot, vol.67, pp.234-243, 2009.

R. Chakravarty, A. Dash, M. Pillai, and M. Venkatesh, Post-elution concentration of 188 Re by an electrochemical method, Appl Radiat Isot, vol.68, pp.2302-2307, 2010.

V. S. Le, N. Morcos, and Z. Bogulski, Development of multiple-elution cartridgebased radioisotope concentrator device for increasing the 99m Tc and 188 Re concentration and the effectiveness of 99m Tc/ 99 Mo utilisation, J Radioanal Nucl Chem, vol.303, pp.1173-1181, 2015.

A. Chhabra, Y. Rathore, P. Bhusari, R. Vatsa, B. R. Mittal et al., Concentration protocol of rhenium-188 perrhenate eluted from tungsten-188/rhenium-188 generator for the preparation of high-yield rhenium-188-labelled radiopharmaceuticals, Nucl Med Commun, vol.39, pp.957-966, 2018.

E. Dadachova and N. Carrasco, The Na/I symporter. (NIS): imaging and therapeutic applications, Semin Nucl Med, vol.34, pp.23-31, 2004.

G. Riesco-eizaguirre and P. Santisteban, A perspective view of sodium iodide symporter research and its clinical implications, Eur J Endocrinol, vol.155, pp.495-512, 2006.

L. S. Zuckier, O. Dohan, Y. Li, C. J. Chang, N. Carrasco et al., Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo, J Nucl Med, vol.45, pp.500-507, 2004.

E. Dadachova, B. Bouzahzah, L. S. Zuckier, and R. G. Pestell, Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter. (NIS), Nucl Med Biol, vol.29, pp.13-21, 2002.

E. Dadachova, A. Nguyen, E. Y. Lin, L. Gnatovskiy, P. Lu et al., Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth, Nucl Med Biol, vol.32, pp.695-700, 2005.

M. J. Willhauck, S. Samani, B. R. Gildehaus, F. J. Wolf, I. Senekowitschschmidtke et al., Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression, J Clin Endocrinol Metab, vol.92, pp.4451-4459, 2007.

K. Klutz, M. J. Willhauck, N. Wunderlich, C. Zach, A. M. Senekowitschschmidtke et al., Sodium iodide symporter. (NIS)-mediated radionuclide. ( 131 I, 188 Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery, Hum Gene Ther, vol.22, pp.1403-1415, 2011.

M. Zhang, S. Shi, R. Guo, Y. Miao, and B. Li, Use of rhenium-188 for in vivo imaging and treatment of human cervical cancer cells transfected with lentivirus expressing sodium iodide symporter, Oncol Rep, vol.36, pp.2289-97, 2016.

Y. Touchefeu, P. Franken, and K. J. Harrington, Radiovirotherapy: principles and prospects in oncology, Curr Pharm Des, vol.18, pp.3313-3333, 2012.

S. Jürgens, W. A. Herrmann, and F. E. Kühn, Rhenium and technetium based radiopharmaceuticals: Development and recent advances, J Organomet Chem, vol.751, pp.83-92, 2014.

A. Piepsz, P. Colarinha, I. Gordon, K. Hahn, P. Olivier et al., Guidelines for 99m Tc-DMSA scintigraphy in children, Eur J Nucl Med, vol.28, pp.37-41, 2001.

S. E. Clarke, C. R. Lazarus, P. Wraight, C. Sampson, and M. M. Pentavalent, MDP-an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid, J Nucl Med, vol.29, pp.33-41, 1988.

C. Bolzati, A. Boschi, L. Uccelli, A. Duatti, R. Franceschini et al., An alternative approach to the preparation of 188Re radiopharmaceuticals from generator-produced, Nucl Med Biol, vol.27, pp.309-323, 2000.

P. J. Blower, A. S. Lam, M. J. O'doherty, A. G. Kettle, A. J. Coakley et al., Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies, Eur J Nucl Med, vol.25, pp.613-634, 1998.

L. García-salinas, G. Ferro-flores, C. Arteaga-murphy, M. Pedrazalópez, S. Hernández-gutiérrez et al., Uptake of the 188 Re(V)-DMSA complex by cervical carcinoma cells in nude mice: pharmacokinetics and dosimetry, Appl Radiat Isot, vol.54, pp.413-421, 2001.

P. J. Blower, A. G. Kettle, M. J. O'doherty, A. J. Coakley, F. F. Knapp et al., V)DMSA quantitatively predicts 188 Re(V)DMSA distribution in patients with prostate cancer metastatic to bone, Eur J Nucl Med, vol.27, pp.1405-1414, 2000.

E. Dadachova and J. Chapman, 188 Re(V)-DMSA revisited: preparation and biodistribution of a potential radiotherapeutic agent with low kidney uptake, Nucl Med Commun, vol.19, pp.173-81, 1998.

A. S. Gdowski, A. Ranjan, and J. K. Vishwanatha, Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials, J Exp Clin Cancer Res, vol.36, p.108, 2017.

V. Damerla, S. Packianathan, P. S. Boerner, A. B. Jani, S. Vijayakumar et al., Recent developments in nuclear medicine in the management of bone metastases: a review and perspective, Am J Clin Oncol, vol.28, pp.513-533, 2005.

K. Liepe and J. Kotzerke, Internal radiotherapy of painful bone metastases, Methods, vol.55, 2011.

G. Rubini, A. Nicoletti, D. Rubini, and A. N. Asabella, Radiometabolic treatment of bone-metastasizing cancer: from 186 rhenium to 223 radium, Cancer Biother Radiopharm, vol.29, pp.1-11, 2014.

A. Sabet, F. Khalaf, T. Haslerud, A. Al-zreiqat, A. Sabet et al., Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis, Am J Nucl Med Mol Imaging, vol.3, pp.437-482, 2013.

M. M. Heck, M. Retz, D. 'alessandria, C. Rauscher, I. Scheidhauer et al., Systemic Radioligand Therapy with 177 Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer, J Urol, vol.196, pp.382-91, 2016.

J. H. Lawrence, L. W. Tuttle, K. G. Scott, and C. L. Connor, Studies on neoplasms with the aid of radioactive phosphorus. I. The total phosphorus metabolism of normal and leukemic mice, J Clin Invest, vol.19, pp.267-71, 1940.

L. Mathieu, P. Chevalier, G. Galy, and M. Berger, Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms

, Int J Appl Radiat Isot, vol.30, pp.725-732, 1979.

F. Hosain and R. P. Spencer, Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background, Semin Nucl Med, vol.22, pp.11-17, 1992.

L. G. Bouchet, W. E. Bolch, S. M. Goddu, R. W. Howell, and D. V. Rao, Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions, J Nucl Med, vol.41, pp.682-689, 2000.

E. K. Pauwels and M. P. Stokkel, Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice, Q J Nucl Med, vol.45, pp.18-26, 2001.

K. Liepe and A. Shinto, From palliative therapy to prolongation of survival: 223 RaCl 2 in the treatment of bone metastases, Ther Adv Med Oncol, vol.8, pp.294-304, 2016.

T. Das and S. Banerjee, Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons, Clin Exp Metastasis, vol.34, pp.1-10, 2017.

E. W. Bouman-wammes, J. De-klerk, H. J. Bloemendal, J. M. Van-dodewaard-de-jong, R. Lange et al., Bone-targeting radiopharmaceuticals as monotherapy or combined with chemotherapy in patients with castrationresistant prostate cancer metastatic to bone, Clin Genitourin Cancer, vol.17, pp.281-92, 2018.

F. Guerra-liberal, A. Tavares, and J. Tavares, Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153, Appl Radiat Isot, vol.110, pp.87-99, 2016.

. Maxon-hr-3rd, L. E. Schroder, L. C. Washburn, S. R. Thomas, R. C. Samaratunga et al., Rhenium-188(Sn)HEDP for treatment of osseous metastases, J Nucl Med, vol.39, pp.659-63, 1998.

H. Palmedo, S. Guhlke, H. Bender, J. Sartor, G. Schoeneich et al., Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases, Eur J Nucl Med, vol.27, pp.123-153, 2000.

E. Savio, J. Gaudiano, A. M. Robles, H. Balter, A. Paolino et al., Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose, BMC Nucl Med, vol.1, 2001.

H. Palmedo, A. Manka-waluch, P. Albers, I. G. Schmidt-wolf, M. Reinhardt et al., Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate, J Clin Oncol, vol.21, pp.2869-75, 2003.

H. J. Biersack, H. Palmedo, A. Andris, S. Rogenhofer, F. Knapp et al., Palliation and survival after repeated 188 Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis, J Nucl Med, vol.52, pp.1721-1727, 2011.

K. Liepe, J. Kropp, R. Hliscs, and W. G. Franke, Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy, Clin Nucl Med, vol.25, pp.901-905, 2000.

K. Liepe, W. G. Franke, J. Kropp, R. Koch, R. Runge et al., Comparison of Rhenium-188, Rhenium-186-HEDP and Strontium-89 in palliation of painful bone metastases, Nuklearmedizin, vol.39, pp.146-51, 2000.

K. Liepe, R. Runge, and J. Kotzerke, The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain, J Cancer Res Clin Oncol, vol.131, pp.60-66, 2005.

K. Liepe and J. Kotzerke, A comparative study of 188 Re-HEDP, 186 Re-HEDP, 153 Sm-EDTMP and 89 Sr in the treatment of painful skeletal metastases

, Nucl Med Commun, vol.28, pp.623-653, 2007.

K. Liepe, R. Hliscs, J. Kropp, R. Runge, F. Knapp et al., Dosimetry of 188 Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases, J Nucl Med, vol.44, pp.953-60, 2003.

K. Liepe, R. Hliscs, J. Kropp, T. Grüning, R. Runge et al., Rhenium-188-HEDP in the palliative treatment of bone metastases, Cancer Biother Radiopharm, vol.15, pp.261-266, 2000.

K. Liepe, J. Kropp, R. Runge, and J. Kotzerke, Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases, Br J Cancer, vol.89, pp.625-634, 2003.

H. Zhang, M. Tian, S. Li, J. Liu, S. Tanada et al., Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients, Cancer Biother Radiopharm, vol.18, pp.719-745, 2003.

S. Li, J. Liu, H. Zhang, M. Tian, J. Wang et al., Rhenium-188 HEDP to treat painful bone metastases, Clin Nucl Med, vol.26, pp.919-941, 2001.

A. Cheng, S. Chen, Y. Zhang, D. Yin, and M. Dong, The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases, Cancer Biother Radiopharm, vol.26, pp.237-281, 2011.

A. S. Shinto, M. B. Mallia, M. Kameswaran, K. K. Kamaleshwaran, J. Joseph et al., Clinical utility of 188 Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies, World J Nucl Med, vol.17, pp.228-263, 2018.

R. Lange, F. Overbeek, J. M. De-klerk, P. Jong, P. C. Van-den-berk et al., Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study, Nuklearmedizin, vol.55, pp.188-95, 2016.

A. Sabet, F. Khalaf, S. Mahjoob, A. Al-zreiqat, H. J. Biersack et al., May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on 188 Re-HEDP treatment in progressive bone metastases after 177 Lu-octreotate, Am J Nucl Med Mol Imaging, vol.4, pp.80-88, 2014.

M. Lam, T. B. Bosma, P. P. Van-rijk, and B. A. Zonnenberg, 188 Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study, Eur J Nucl Med Mol Imaging, vol.369, pp.1425-1458, 2009.

R. Lange, R. Ter-heine, W. N. Van-wieringen, A. M. Tromp, M. Paap et al., Cytotoxic effects of the therapeutic radionuclide rhenium-188 combined with taxanes in human prostate carcinoma cell lines, Cancer Biother Radiopharm, vol.32, pp.16-23, 2017.

E. S. Verdera, J. Gaudiano, A. Leon, G. Martinez, A. Robles et al., Rhenium-188-HEDP-kit formulation and quality control, Radiochim Acta, vol.2, pp.113-120, 1997.

K. Hashimoto, Synthesis of a 188 Re-HEDP complex using carrier-free 188 Re, and a study of its stability, Appl Radiat Isot, vol.49, pp.351-357, 1998.

B. T. Hsieh, J. F. Hsieh, S. C. Tsai, W. Y. Lin, S. J. Wang et al., Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases, Nucl Med Biol, vol.26, pp.973-979, 1999.

W. Y. Lin, J. F. Hsieh, C. P. Lin, B. T. Hsieh, G. Ting et al., Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes, Nucl Med Biol, vol.26, pp.455-464, 1999.

V. M. Petriev, Influence of reactant concentrations and solution acidity on the complexation of 188 Re with 1-hydroxyethane-1,1-diphosphonic acid, Radiochemistry, vol.50, pp.203-210, 2008.

M. Y. Nassar, M. T. El-kolaly, and M. Mahran, Synthesis of a 188 Re-HEDP complex using carrier-free 188 Re and a study of its stability and biological distribution, Radiochemistry, vol.53, pp.352-358, 2011.

V. K. Shiryaeva, V. M. Petriev, A. A. Bryukhanova, O. A. Smoryzanova, V. G. Skvortsov et al., Evaluation of the influence of preparation conditions on pharmacokinetics of bone-seeking radiopharmaceutical 188Re-labeled hydroxyethylidenediphosphonic acid monopotassium salt in rats, Pharm Chem J, vol.46, pp.443-451, 2012.

R. Lange, J. De-klerk, H. J. Bloemendal, R. M. Ramakers, F. J. Beekman et al., Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188 Rhenium-HEDP, Nucl Med Biol, vol.42, pp.465-474, 2015.

R. Lange, T. Heine, R. Van-der-gronde, T. Selles, S. De-klerk et al., Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical

R. Ter-heine, R. Lange, O. B. Breukels, H. J. Bloemendal, R. G. Rummenie et al., Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases, Eur J Pharm Sci, vol.30, pp.317-341, 2014.

T. Kochetova, V. Krylov, M. Smolyarchuk, D. Sokov, A. Lunev et al., 188 Re zoledronic acid in the palliative treatment of painful bone metastases, Int J Nucl Med Res, pp.92-100, 2017.

R. Lange, T. Heine, R. Knapp, F. Russ, ). De-klerk et al., Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases, Bone, vol.91, pp.159-79, 2016.

C. Ansquer, F. Kraeber-bodéré, and J. F. Chatal, Current status and perspectives in peptide receptor radiation therapy, Curr Pharm Des, vol.15, pp.2453-62, 2009.

C. Lozza, I. Navarro-teulon, A. Pèlegrin, J. P. Pouget, and E. Vivès, Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers, Front Oncol, vol.3, p.247, 2013.

A. Dash, S. Chakraborty, M. R. Pillai, and F. F. Knapp, Russ) Jr. Peptide receptor radionuclide therapy: an overview, Cancer Biother Radiopharm, vol.30, pp.47-71, 2015.

S. M. Larson, J. A. Carrasquillo, N. K. Cheung, and O. W. Press, Radioimmunotherapy of human tumours, Nat Rev Cancer, vol.15, pp.347-60, 2015.

F. Kraeber-bodéré, J. Barbet, and J. F. Chatal, Radioimmunotherapy: from current clinical success to future industrial breakthrough?, J Nucl Med, vol.57, pp.329-360, 2016.

D. M. Goldenberg and R. M. Sharkey, Advances in cancer therapy with radiolabeled monoclonal antibodies, Q J Nucl Med Mol Imaging, vol.50, pp.248-64, 2006.

L. Uccelli, P. Martini, M. Pasquali, and A. Boschi, Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy, Biomed Res Int, p.5923609, 2017.

D. Bunjes, 188 Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia, Leukemia Lymphoma, vol.43, pp.2125-2156, 2002.

D. Decker, M. Bacher, K. Thierens, H. Slegers, G. Dierckx et al., De Vos F. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of Bcell chronic lymphocytic leukemia, Nucl Med Biol, vol.35, pp.599-604, 2008.

E. Torres-garcía, G. Ferro-flores, A. De-murphy, C. Correa-gonzález, L. Pichardo-romero et al., Biokinetics and dosimetry of 188 Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience, Arch Med Res, vol.39, pp.100-109, 2008.

G. Li, Y. Wang, K. Huang, H. Zhang, W. Peng et al., The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188 Re-herceptin, Nucl Med Biol, vol.32, pp.59-65, 2005.

T. Y. Luo, I. C. Tang, Y. L. Wu, K. L. Hsu, S. W. Liu et al., Evaluating the potential of 188 Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment, Nucl Med Biol, vol.36, pp.81-89, 2009.

H. Y. Wang, W. Y. Lin, M. C. Chen, T. Lin, C. H. Chao et al., Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma, Int J Radiat Biol, vol.89, pp.346-55, 2013.

J. Xiao, X. Xu, X. Li, Y. Li, G. Liu et al., Re-188 enhances the inhibitory effect of bevacizumab in non-small-cell lung cancer, Molecules, vol.21, p.1308, 2016.

W. I. Kuo, K. H. Cheng, Y. J. Chang, T. T. Wu, W. C. Hsu et al., Characteristics and NanoSPECT/CT Imaging of 188 Recetuximab in NCI-H292 Human Lung Cancer Xenografts, Anticancer Res, vol.39, pp.183-90, 2019.

B. O. González-navarro, A. Casaco, M. León, R. Leyva, A. León et al., High dose of hR-3, an anti-epidermal growth factor receptor monoclonal antibody labeled with 188 rhenium following intravenous injection into rats, J Appl Res, vol.6, pp.77-88, 2006.

M. Juweid, R. M. Sharkey, L. C. Swayne, G. L. Griffiths, R. Dunn et al., Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anticarcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer, J Nucl Med, vol.39, pp.34-42, 1998.

A. Murray, M. S. Simms, D. P. Scholfield, R. M. Vincent, G. Denton et al., Production and characterization of 188 Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer, J Nucl Med, vol.42, pp.726-758, 2001.

D. S. Geller, J. Morris, E. Revskaya, M. Kahn, W. Zhang et al., Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R), Nucl Med Biol, vol.43, pp.812-819, 2016.

C. H. Chang, L. C. Tsai, S. T. Chen, C. C. Yuan, M. W. Hung et al., Radioimmunotherapy and apoptotic induction on Ck19-overexpressing human cervical carcinoma cells with Re

, Anticancer Res, vol.25, pp.2719-2747, 2005.

R. Phaeton, Z. Jiang, E. Revskaya, D. R. Fisher, G. L. Goldberg et al., Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer, Cancer Med, vol.5, pp.9-16, 2016.

W. Quispe-tintaya, D. Chandra, A. Jahangir, M. Harris, A. Casadevall et al., Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer, Proc Natl Acad Sci, vol.110, pp.8668-73, 2013.

J. D. Nosanchuk, A. Jeyakumar, A. Ray, E. Revskaya, Z. Jiang et al., Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy, Sci Rep, vol.8, p.5466, 2018.

U. Seitz, B. Neumaier, G. Glatting, J. Kotzerke, D. Bunjes et al., Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia, Eur J Nucl Med, vol.26, pp.1265-73, 1999.

D. Bunjes, I. Buchmann, C. Duncker, U. Seitz, J. Kotzerke et al., Rhenium 188-labeled anti-CD66. (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study, Blood, vol.98, pp.565-72, 2001.

I. Buchmann, D. Bunjes, J. Kotzerke, H. Martin, G. Glatting et al., Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities, Cancer Biother Radiopharm, vol.17, pp.151-63, 2002.

M. Ringhoffer, N. Blumstein, B. Neumaier, G. Glatting, V. Harsdorf et al., 188 Re or 90 Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

, Br J Haematol, vol.130, pp.604-617, 2005.

A. Lauter, A. Strumpf, U. Platzbecker, J. Schetelig, M. Wermke et al., 188 Re anti-CD66 radioimmunotherapy combined with reducedintensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation, Br J Haematol, vol.148, pp.910-917, 2010.

S. A. Klein, S. Hermann, J. W. Dietrich, D. Hoelzer, and H. Martin, Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies, Blood, vol.99, pp.2270-2271, 2002.

T. Zenz, R. F. Schlenk, G. Glatting, B. Neumaier, N. Blumstein et al., Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation, J Nucl Med, vol.47, pp.278-86, 2006.

S. Schneider, A. Strumpf, J. Schetelig, G. Wunderlich, G. Ehninger et al., Reduced-intensity conditioning combined with 188 Rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: the role of in vivo t cell depletion, Biol Blood Marrow Transplant, vol.21, pp.1754-60, 2015.

Y. Zhi, Z. Meiying, L. Baohe, Z. Changying, H. Yan et al., 188 Relabelled McAb 3H11 used as preventive for the peritoneal micro-metastasis of gastric cancer, Nuclear Science and Techniques, vol.10, pp.203-209, 1999.

L. A. Torres, M. A. Coca, J. F. Batista, A. Casaco, G. Lopez et al., Biodistribution and internal dosimetry of the 188 Re-labelled humanized monoclonal antibody anti-epidermal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas, Nucl Med Commun, vol.29, pp.66-75, 2008.

A. Casacó, G. López, I. García, J. A. Rodríguez, R. Fernández et al., Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma, Cancer Biol Ther, vol.7, pp.333-342, 2008.

M. Klein, M. Lotem, T. Peretz, S. T. Zwas, S. Mizrachi et al., Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma, J Skin Cancer, p.828329, 2013.

E. Dadachova, J. D. Nosanchuk, L. Shi, A. D. Schweitzer, A. Frenkel et al., Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin, Proc Natl Acad Sci, vol.101, 2004.

E. Dadachova, A. Nakouzi, R. A. Bryan, and A. Casadevall, Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection, Proc Natl Acad Sci, vol.100, pp.10942-10949, 2003.

J. Rivera, A. S. Nakouzi, A. Morgenstern, F. Bruchertseifer, E. Dadachova et al., Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax, Antimicrob Agents Chemother, vol.53, pp.4860-4868, 2009.

E. Dadachova, M. C. Patel, S. Toussi, C. Apostolidis, A. Morgenstern et al., Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins, PLoS Med, vol.3, p.427, 2006.

C. Bolzati, D. Carta, N. Salvarese, and F. Refosco, Chelating systems for 99m Tc/ 188 Re in the development of radiolabeled peptide pharmaceuticals, Anticancer Agents Med Chem, vol.12, pp.428-61, 2012.

R. C. Howell, E. Revskaya, V. Pazo, J. D. Nosanchuk, A. Casadevall et al., Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma, Bioconjug Chem, vol.18, pp.1739-1787, 2007.

Y. Li, L. Ma, V. Gaddam, F. Gallazzi, H. M. Hennkens et al., Synthesis, characterization, and in vitro evaluation of new 99m Tc/Re(V)-cyclized octreotide analogues: an experimental and computational approach, Inorg Chem, vol.55, pp.1124-1157, 2016.

P. O. Zamora, M. J. Marek, F. Knapp, and ). Russ, Preparation of 188 Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy, Appl Radiat Isot, vol.48, pp.226-232, 1997.

C. Arteaga-de-murphy, M. Pedraza-lópez, G. Ferro-flores, E. Murphy-stack, L. Chávez-mercado et al., Uptake of 188 Re-beta-naphthylpeptide in cervical carcinoma tumours in athymic mice, Nucl Med Biol, vol.28, pp.319-345, 2001.

E. M. Molina-trinidad, C. A. De-murphy, G. Ferro-flores, E. Murphy-stack, J. et al., Radiopharmacokinetic and dosimetric parameters of 188 Relanreotide in athymic mice with induced human cancer tumors, Int J Pharm, vol.310, pp.125-155, 2006.

J. E. Cyr, D. A. Pearson, D. M. Wilson, C. A. Nelson, M. Guaraldi et al., Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies, J Med Chem, vol.50, pp.1354-64, 2007.

F. Yu, M. Lv, H. Cai, D. Li, X. Yuan et al., Therapeutic effect of 188 Re-MAG 3 -depreotide on non-small cell lung cancer in vivo and in vitro, Int J Clin Exp Pathol, vol.6, pp.421-451, 2013.

L. Cui, Z. Liu, J. X. Jia, B. Li, F. Wang et al., Evaluation of 188 Re-MAG2-RGD-bombesin for potential prostate cancer therapy, Nucl Med Biol, vol.40, pp.182-191, 2013.

W. Kan, Z. Zhou, H. Wei, and Z. Zhong, Effective way to radiolabel the peptide of MAG 3 -RM26 with 188 Re and the study on its coordination chemistry, J Radioanal Nucl Chem, vol.314, pp.2087-90, 2017.

K. Smilkov, E. Janevik, R. Guerrini, M. Pasquali, A. Boschi et al., Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with Substance-P, Appl Radiat Isot, vol.92, pp.25-31, 2014.

Y. Li, Y. Hu, J. Xiao, G. Liu, X. Li et al., Investigation of SP94 Peptide as a specific probe for hepatocellular carcinoma imaging and therapy, vol.6, p.33511, 2016.

X. Zhang, S. Feng, J. Liu, Q. Li, L. Zheng et al., Novel small peptides derived from VEGF 125?136 : potential drugs for radioactive diagnosis and therapy in A549 tumor-bearing nude mice, vol.7, p.4278, 2017.

S. H. Wang, A. C. Lee, I. J. Chen, N. C. Chang, H. C. Wu et al., Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy, Biomaterials, vol.94, pp.31-44, 2016.

Y. Miao and T. P. Quinn, Peptide-targeted radionuclide therapy for melanoma, Crit Rev Oncol Hematol, vol.67, pp.213-241, 2008.

D. Carta, N. Salvarese, N. Morellato, F. Gao, W. Sihver et al., -labeled ?-melanocyte stimulating hormone peptide analogs: effects of cyclization on the radiopharmaceutical properties, Nucl Med Biol, vol.43, pp.788-801, 2016.

M. J. Edelman, G. Clamon, D. Kahn, M. Magram, J. Lister-james et al., Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog, J Thorac Oncol, vol.4, pp.1550-1554, 2009.

N. Khajornjiraphan, N. A. Thu, and P. K. Chow, Yttrium-90 microspheres: a review of its emerging clinical indications, Liver Cancer, vol.4, pp.6-15, 2015.

M. F. Bozkurt, B. V. Salanci, and Ö. Ugur, Intra-arterial radionuclide therapies for liver tumors, Semin Nucl Med, vol.46, pp.324-363, 2016.

C. Bouvry, X. Palard, E. J. Ardisson, V. Loyer, P. Garin et al., Transarterial radioembolisation (TARE) agents beyond 90 Y-microspheres

, Biomed Res Int, p.1435302, 2018.

N. Lepareur and E. Garin, Transarterial radionuclide therapy with 188 Re-labelled lipiodol, Int J Nucl Med Res, pp.79-91, 2017.

J. C. Paeng, J. M. Jeong, C. J. Yoon, Y. S. Lee, Y. G. Suh et al., Lipiodol solution of 188 Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model, J Nucl Med, vol.44, pp.2033-2041, 2003.

A. Boschi, L. Uccelli, A. Duatti, P. Colamussi, C. Cittanti et al., A kit formulation for the preparation of 188 Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma, Nucl Med Commun, vol.25, pp.691-700, 2004.

N. Lepareur, V. Ardisson, N. Noiret, and E. Garin, 188 Re-SSS/Lipiodol: development of a potential treatment for HCC from bench to bedside, Int J Mol Imaging, p.278306, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00866975

G. H. Keng, F. X. Sundram, S. W. Yu, S. Somanesan, J. Premaraj et al., Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radioconjugates, Ann Acad Med, vol.31, pp.382-388, 2002.

F. Sundram, T. Chau, P. Onkhuudai, P. Bernal, and A. K. Padhy, Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, vol.31, pp.250-257, 2004.

K. De-ruyck, B. Lambert, K. Bacher, F. Gemmel, D. Vos et al., Biologic dosimetry of 188 Re-HDD/Lipiodol versus 131 I-Lipiodol therapy in patients with hepatocellular carcinoma, J Nucl Med, vol.45, pp.612-620, 2004.

B. Lambert, K. Bacher, L. Defreyne, F. Gemmel, H. Van-vlierberghe et al., 188 Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial, J Nucl Med, vol.46, pp.60-66, 2005.

B. Lambert, K. Bacher, D. Keukeleire, K. Smeets, P. Colle et al., 188 Re-HDD/Lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis, J Nucl Med, vol.46, pp.1326-1358, 2005.

B. Lambert, M. Praet, P. Vanlangenhove, R. Troisi, B. De-hemptinne et al., Radiolabeled Lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome, Cancer Biother Radiopharm, vol.20, pp.209-223, 2005.

A. Kumar, C. Bal, D. N. Srivastava, S. K. Acharya, S. P. Thulkar et al., Transarterial radionuclide therapy with Re-188-HDD-lipiodol in case of unresectable hepatocellular carcinoma with extensive portal vein thrombosis, Eur J Radiology Extra, vol.56, pp.55-64, 2005.

A. Kumar, D. N. Srivastava, and C. Bal, Management of postsurgical recurrence of hepatocellular carcinoma with Rhenium 188-HDD labeled iodized oil

, J Vasc Interv Radiol, vol.17, pp.157-161, 2006.

A. Kumar, C. Bal, D. N. Srivastava, S. P. Thulkar, S. Sharma et al., Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-Lipiodol, Eur J Gastroenterol Hepatol, vol.18, pp.219-222, 2006.

B. Lambert, K. Bacher, L. Defreyne, H. Van-vlierberghe, J. M. Jeong et al., 188 Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study, Eur J Nucl Med Mol Imaging, vol.33, pp.344-52, 2006.

A. Kumar, D. N. Srivastava, T. Chau, H. D. Long, C. Bal et al., Inoperable hepatocellular carcinoma: transarterial 188 Re HDD-labeled iodized oil for treatment prospective multicenter clinical trial, Radiology, vol.243, pp.509-528, 2007.

P. Bernal, J. L. Raoul, G. Vidmar, E. Sereegotov, F. X. Sundram et al., Intra-arterial Rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study, Int J Radiat Oncol Biol Phys, vol.69, pp.1448-55, 2007.

P. Bernal, J. L. Raoul, J. Stare, E. Sereegotov, F. X. Sundram et al., International Atomic Energy Agency sponsored multination study of intra-arterial rhenium-188-labeled Lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study, Sem Nucl Med, vol.38, pp.40-45, 2008.

P. L. Esquinas, A. Shinto, K. K. Kamaleshwaran, J. Joseph, and A. Celler, Biodistribution, pharmacokinetics, and organ-level dosimetry for 188 Re-AHDDLipiodol radioembolization based on quantitative post-treatment SPECT/CT scans, EJNMMI Physics, vol.5, p.30, 2018.

K. Delaunay, E. Garin, Y. Rolland, N. Lepareur, S. Laffont et al., Biodistribution and dosimetry assessments for hepatocellular carcinoma treated with 188 Re-SSS Lipiodol: Preliminary results of the phase 1 trial Lip Re 1, J Nucl Med, vol.59, p.602, 2018.

A. K. Padhy and M. Dondi, Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry, Semin Nucl Med, vol.38, pp.5-12, 2008.

V. K. Banka, S. H. Moon, J. M. Jeong, S. R. Seelam, Y. S. Lee et al., Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol. (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol, Nucl Med Biol, vol.42, pp.317-322, 2015.

S. D. Conzone, U. O. Häfeli, D. E. Day, and G. J. Ehrhardt, Preparation and properties of radioactive rhenium glass microspheres intended for in vivo radioembolization therapy, J Biomed Mater Res, vol.42, pp.617-642, 1998.

S. J. Wang, W. Y. Lin, M. N. Chen, C. S. Chi, J. T. Chen et al., Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma, J Nucl Med, vol.39, pp.1752-1759, 1998.

G. Wunderlich, J. Pinkert, M. Stintz, and J. Kotzerke, Labeling and biodistribution of different particle materials for radioembolization therapy with 188 Re, Appl Radiat Isot, vol.62, pp.745-50, 2005.

E. Verger, P. Drion, G. Meffre, C. Bernard, L. Duwez et al., 68 Ga and 188 Re starch-based microparticles as theranostic tool for the hepatocellular carcinoma: radiolabeling and preliminary in vivo rat studies, PLoS ONE, vol.11, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01398433

K. Liepe, C. Brogsitter, J. Leonhard, G. Wunderlich, R. Hliscs et al., Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization, Jpn J Clin Oncol, vol.37, pp.942-50, 2007.

M. L. Nowicki, J. B. Cwikla, A. J. Sankowski, S. Shcherbinin, J. Grimmes et al., Initial study of radiological and clinical efficacy radioembolization using 188 Re-human serum albumin. (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers, Med Sci Monit, vol.20, pp.1353-62, 2014.

K. Liepe, J. Kotzerke, and B. Lambert, Advantage of 188 Re-radiopharmaceuticals in hepatocellular cancer and liver metastases, J Nucl Med, vol.46, pp.1407-1415, 2005.

C. A. Hoefnagel, Radionuclide therapy revisited, Eur J Nucl Med, vol.18, pp.408-439, 1991.

F. D. Chen, B. T. Hsieh, H. E. Wang, Y. H. Ou, W. K. Yang et al., Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals, Nucl Med Biol, vol.28, pp.835-879, 2001.

U. O. Häfeli, G. J. Pauer, J. Unnithan, and R. A. Prayson, Fibrin glue system for adjuvant brachytherapy of brain tumors with 188 Re and 186 Relabeled microspheres, Eur J Pharm Biopharm, vol.65, pp.282-290, 2007.

C. Vanpouille-box, F. Lacoeuille, C. Belloche, N. Lepareur, L. Lemaire et al., Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with 188 Re-lipid nanocapsules, Biomaterials, vol.32, pp.6781-90, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00638699

A. Cikankowitz, A. Clavreul, C. Tétaud, L. Lemaire, A. Rousseau et al., Characterization of the distribution, retention, and efficacy of internal radiation of 188 Re-lipid nanocapsules in an immunocompromised human glioblastoma model, J Neurooncol, vol.131, pp.49-58, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01451658

D. Séhédic, I. Chourpa, C. Tétaud, A. Griveau, C. Loussouarn et al., Locoregional confinement and major clinical benefit of 188 Re-Loaded CXCR4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma, Theranostics, vol.7, pp.4517-4553, 2017.

B. A. Hrycushko, A. N. Gutierrez, B. Goins, W. Yan, W. T. Phillips et al., Radiobiological characterization of post-lumpectomy focal brachytherapy with lipid nanoparticle-carried radionuclides, Phys Med Biol, vol.56, pp.703-722, 2011.

B. A. Hrycushko, S. Li, C. Shi, B. Goins, Y. Liu et al., Postlumpectomy focal brachytherapy for simultaneous treatment of surgical cavity and draining lymph nodes, Int J Radiat Oncol Biol Phys, vol.79, pp.948-55, 2011.

B. A. Hrycushko, S. Li, B. Goins, R. A. Otto, and A. Bao, Direct intratumoral infusion of liposome encapsulated rhenium radionuclides for cancer therapy: effects of nonuniform intratumoral dose distribution, Med Phys, vol.38, pp.1339-1386, 2011.

B. A. Hrycushko, S. Ware, S. Li, and A. Bao, Improved tumour response prediction with equivalent uniform dose in pre-clinical study using direct intratumoural infusion of liposome-encapsulated 86 Re radionuclides, Phys Med Biol, vol.56, pp.5721-5755, 2011.

C. M. Chang, K. L. Lan, W. S. Huang, Y. J. Lee, T. W. Lee et al., 188 Reliposome can induce mitochondrialautophagy and reverse drug resistance for ovarian cancer: from bench evidence to preliminary clinical proof-ofconcept, Int J Mol Sci, vol.18, p.903, 2017.

K. Liepe, J. J. Zaknun, A. Padhy, E. Barrenechea, V. Soroa et al., Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee, Ann Nucl Med, vol.25, pp.317-340, 2011.

J. M. Jeong, Y. J. Lee, E. H. Kim, Y. S. Chang, Y. J. Kim et al., Preparation of 188 Re-labeled paper for treating skin cancer, Appl Radiat Isot, vol.58, pp.551-556, 2003.

P. Bhusari, J. Shukla, M. Kumar, R. Vatsa, A. Chhabra et al., Noninvasive treatment of keloid using customized Re-188 skin patch

, Dermatol Ther, vol.30, 2017.

J. Shukla and B. R. Mittal, 188 Re Tailor Made Skin Patch for the treatment of skin cancers and keloid: overview and technical considerations, Int J Nucl Med Res, pp.107-113, 2017.

A. F. Sedda, G. Rossi, C. Cipriani, A. M. Carrozzo, and P. Donati, Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma, Clin Exp Dermatol, vol.33, pp.745-754, 2008.

C. Cipriani, B. Frisch, K. Scheidhauer, and M. Desantis, Personalized highdose-rate brachytherapy with non-sealed rhenium-188 in non-melanoma skin cancer, Int J Nucl Med Res, pp.114-136, 2017.

A. M. Carrozzo, A. F. Sedda, L. Muscardin, P. Donati, and C. Cipriani, Dermo beta brachytherapy with 188 Re in squamous cell carcinoma of the penis: a new therapy, Eur J Dermatol, vol.23, pp.183-191, 2013.

A. M. Carrozzo, C. Cipriani, P. Donati, L. Muscardin, and A. F. Sedda, Dermo Beta Brachytherapy with 188 Re in extramammary Paget's disease, G Ital Dermatol Venereol, vol.149, pp.115-136, 2014.